Results 221 to 230 of about 29,336 (265)
Some of the next articles are maybe not open access.
Hydralazine for essential hypertension
Cochrane Database of Systematic Reviews, 2011Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950's. Although it has largely been replaced by newer antihypertensive drugs with more acceptable tolerability profiles, hydralazine ...
Michael R, Kandler +4 more
openaire +2 more sources
Management of Essential Hypertension
Cardiology Clinics, 2017The treatment of essential hypertension is one of the most critical interventions to decrease cardiovascular morbidity and mortality. The prevalence of hypertension in the US varies across race/ethnicity with African Americans having the highest prevalence and overall less control among racial/ethnic minorities compared with non-Hispanic whites ...
Keith C, Ferdinand, Samar A, Nasser
openaire +2 more sources
Nonmodulation and essential hypertension
Current Hypertension Reports, 2006Nonmodulation is a process in which there is a disorder in angiotensin-dependent control of the renal circulation and adrenal aldosterone release. The abnormalities are associated with an inability to handle a sodium load and salt-sensitive hypertension. All of the features are corrected by angiotensin-converting enzyme inhibition.
Norman K, Hollenberg, Gordon H, Williams
openaire +2 more sources
Microalbuminuria in essential hypertension
Current Opinion in Nephrology and Hypertension, 1999Urinary excretion of albumin exceeds normal values in 10 to 25% of patients with essential hypertension. The level of albuminuria is highly correlated with arterial pressure, and more closely with ambulatory arterial pressure. The interaction between albuminuria and arterial pressure is enhanced by overweight, smoking, protein intake, insulin ...
A, Mimran, J, Ribstein, G, Du Cailar
openaire +2 more sources
Guanabenz in essential hypertension
Clinical Pharmacology & Therapeutics, 1977Fifty‐five patients with mild to moderately severe essential hypertension were treated with guanabenz (2,6‐dichlorobenzylidene aminoguanidine acetate) in doses from 4 to 16 mg twice daily in a randomized, placebo‐controlled study. The patients treated with placebo in the initial phase of the study were subsequently treated with guanabenz.
F G, McMahon +4 more
openaire +2 more sources
Pharmacotherapy of Essential Hypertension
American Journal of Health-System Pharmacy, 1975Practical clinical aspects of the evaluation and treatment of essential hypertension are reviewed. Drug therapy discussed includes diuretics, and as adjunctive therapy, sympathoplegic agents, peripheral vasodilators and beta blockers. Also covered are treatment of less common forms of essential hypertension, other forms of antihypertensive therapy, and
D W, Duhme, D J, Greenblatt, R R, Miller
openaire +3 more sources
Catecholamines and essential hypertension
Baillière's Clinical Endocrinology and Metabolism, 1993Given the ubiquitous distribution of catecholamines in mammals, and their importance in a range of physiological processes pivotal to blood pressure regulation, the subject of catecholamines and essential hypertension has a broader context than simply consideration of sympathetic nervous system and adrenal medullary dysfunction.
openaire +2 more sources
Essential Hypertension in Children
Hospital Practice, 1982Since the adverse effects of hypertension on cardiovascular function can in large measure be prevented by treatment it would seem logical to identify, early in life, persons who are at risk of becoming hypertensive. But tracking and managing children found to have elevated blood pressure pose a serious risk of overdiagnosis and overtreatment, with ...
openaire +2 more sources
Journal of the American Pharmaceutical Association (1961), 1971
J L, Hirschman, E T, Herfindal
openaire +2 more sources
J L, Hirschman, E T, Herfindal
openaire +2 more sources